Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | DPP4 | P27487 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.47 |
| ▸ | KLK7 | P49862 | 1/20 | 0.46 |
| ▸ | FPR3 | P25089 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443517 | 0.89 | SLC6A2 (0.47) | OPRD1KDM1AHRH3FPR3FPR2 | |
| SCHEMBL25650104 | 0.89 | OPRD1 (0.52) | OPRD1KDM1AHRH3DPP4PRMT5 | |
| SCHEMBL1682323 | 0.89 | OPRD1 (0.52) | OPRD1KDM1AHRH3DPP4PRMT5 | |
| SCHEMBL3025802 | 0.87 | HDAC1 (0.45) | OPRD1KDM1AHRH3DPP4FPR3 | |
| SCHEMBL25449146 | 0.86 | PRMT5 (0.47) | OPRD1KDM1APRMT5KLK7FPR3 | |
| SCHEMBL3046705 | 0.85 | KLK7 (0.49) | OPRD1KDM1AKLK7MEN1KMT2A | |
| SCHEMBL13086596 | 0.85 | KLK7 (0.49) | OPRD1KDM1AKLK7MEN1KMT2A | |
| SCHEMBL2689602 | 0.85 | KLK7 (0.49) | OPRD1KDM1AKLK7MEN1KMT2A | |
| SCHEMBL13034261 | 0.83 | KLK7 (0.46) | OPRD1KDM1AHRH3PRMT5KLK7 | |
| SCHEMBL13086758 | 0.83 | MEN1 (0.50) | OPRD1KLK7EPHX2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1883627-B1 | BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC (CA) | 2018-04-18 | — | — | EP | disclosed |
| EP-2534170-B1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC (CA) | 2017-04-19 | — | — | EP | disclosed |
| US-9284350-B2 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2016-03-15 | — | — | US | disclosed |
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| US-8648094-B2 | IAP BIR domain binding compounds | PHARMASCIENCE, INC. (CA) | 2014-02-11 | — | — | US | disclosed |
| US-8575113-B2 | BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2013-11-05 | — | — | US | disclosed |
| US-8575113-B2 | BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2013-11-05 | — | — | US | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | PHARMASCIENCE INC. (CA) | 2013-02-14 | — | — | US | disclosed |
| US-20120195915-A1 | IAP BIR domain binding compounds | PHARMASCIENCE INC. (CA) | 2012-08-02 | — | — | US | disclosed |
| US-20110171171-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2011-07-14 | — | — | US | disclosed |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-11-18 | — | — | US | disclosed |
| US-7772177-B2 | BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| US-7772177-B2 | BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-10 | — | — | US | disclosed |
| WO-2009155709-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-12-30 | — | — | WO | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2009-07-30 | — | — | US | disclosed |
| WO-2007131366-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC. (CA) | 2007-11-22 | — | — | WO | disclosed |
| WO-2006122408-A9 | BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS INC (CA) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040892-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | OPRD1 4772/4885KDM1A 2189/4885HRH3 4437/4885 |
| US-20100292269-A1 | BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC3, BIRC2 | OPRD1 3588/4885KDM1A 2525/4885HRH3 3409/4885 |
| US-20120195915-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC3 | OPRD1 4379/4885KDM1A 2086/4885HRH3 3348/4885 |
| US-20090192140-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | OPRD1 4379/4885KDM1A 2086/4885HRH3 3348/4885 |
| US-20110171171-A1 | BRIDGED SECONDARY AMINES AND USE THEREOF AS IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC7 | OPRD1 4631/4885KDM1A 1123/4885HRH3 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.